About ProciseDx
ProciseDx is a company based in San Diego (United States) founded in 2018 was acquired by Biosynex in June 2023. ProciseDx has raised $8.96 million across 3 funding rounds from investors including Nestlé Health Science and Biosynex. ProciseDx offers products and services including Drug Monitoring Assays and ProciseDx Platform. ProciseDx operates in a competitive market with competitors including EKF, LumiraDx, SpinChip, LightDeck Diagnostics and EDX Medical Group, among others.
- Headquarter San Diego, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$8.96 M (USD)
in 3 rounds
-
Latest Funding Round
$13 M (USD), Debt – Convertible
Jul 13, 2021
-
Investors
Nestlé Health Science
& 1 more
-
Employee Count
Not available
-
Acquired by
Biosynex
(Jun 12, 2023)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of ProciseDx
ProciseDx offers a comprehensive portfolio of products and services, including Drug Monitoring Assays and ProciseDx Platform.
Provide quick, accurate drug level measurements from blood samples.
Enables immediate clinical decisions with quantitative immunoassays.
Funding Insights of ProciseDx
ProciseDx has successfully raised a total of $8.96M across 3 strategic funding rounds. The most recent funding activity was a Debt – Convertible round of $13 million completed in July 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in ProciseDx
ProciseDx has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Nestlé Health Science and Biosynex.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Nutritional dietary supplements are provided for health and wellness needs.
|
Locked | Locked | Locked | |
|
Professional rapid diagnostic tests for diseases are manufactured by Biosynex.
|
Locked | Locked | Locked |
Investor details for ProciseDx
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by ProciseDx
Investment portfolio details for ProciseDx
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - ProciseDx
Detailed financials for ProciseDx
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Procisedx Comparisons
Peer comparison for ProciseDx
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of ProciseDx
ProciseDx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as EKF, LumiraDx, SpinChip, LightDeck Diagnostics and EDX Medical Group, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Point-of-care and laboratory blood analyzers are developed by EKF.
|
|
| Locked | Locked | Locked |
Cloud based diagnostics platform for point of care diagnosing
|
|
| Locked | Locked | Locked |
In-vitro diagnostic test cartridges are developed and manufactured via R&D.
|
|
| Locked | Locked | Locked |
Point-of-care diagnostic devices for multiplex assays are developed.
|
|
| Locked | Locked | Locked |
Medical diagnostics solutions are researched by the laboratory.
|
Detailed competitors of ProciseDx
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Procisedx
Complete news archive for ProciseDx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ProciseDx
ProciseDx was founded in 2018 and raised its 1st funding round 2 years after it was founded.
ProciseDx is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Larry Mimms is the current CEO of ProciseDx.
ProciseDx is a funded company, having raised a total of $8.96M across 3 funding rounds to date.
ProciseDx was established in 2018 in San Diego, United States, within the healthcare diagnostics sector. A point-of-care device is supplied to professionals for clinical analysis. Proprietary Lumiphore technology is employed to measure patient samples, including blood, urine, and stool, in immunoassay procedures. Results from the device are used by healthcare providers to support diagnosis and treatment decisions in various settings.
ProciseDx offers Drug Monitoring Assays and ProciseDx Platform.
ProciseDx has 2 investors. Key investors include Nestlé Health Science, and Biosynex.